Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?
TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News Vesper Bio reports 95% CSF progranulin boost in FTD-GRN trial—what’s next for VES001? Vesper Bio’s oral FTD therapy VES001 boosts CSF progranulin by 95%. Explore what this means for dementia prevention and future clinical milestones. bySrinathOctober 31, 2025